Answers are grounded in this paper and cite their sources.
SARS-CoV, SARS-CoV-2, and MERS-CoV continue to infect humans or pose a threat of future outbreaks, highlighting the ongoing need for effective, broad-spectrum therapeutics that target these highly pathogenic coronaviruses. As single-domain antibodies, nanobodies have a small size, high target-binding affinity, exceptional stability, low production costs, and the ability to access otherwise hidden or cryptic epitopes. Here, we identified nanobodies targeting SARS-CoV, SARS-CoV-2, and MERS-CoV receptor-binding domains (RBDs) using phage display libraries derived from immunized nanomice and generated a bispecific nanobody to evaluate its broadly neutralizing activity and cross-protective efficacy. Nanobodies 2F11 and 4D6 targeted SARS-CoV RBD, potently neutralizing the SARS-CoV original (Tor2) strain, whereas nanobody 3B11 targeted both SARS-CoV and SARS-CoV-2 RBDs, broadly neutralizing all three SARS-CoV strains (Tor2, GD03, and SZ3) and divergent SARS-CoV-2 variants. Among MERS-CoV RBD-targeting nanobodies, 1C11 demonstrated broadly neutralizing activity against multiple MERS-CoV strains, while its Fc-fused version substantially enhanced the neutralizing potency. These nanobodies exerted neutralizing effects by blocking the interaction between the RBDs and their respective receptors. Cryo-EM structures, computational modeling, and epitope-mapping analyses revealed unique epitopes of 2F11, 3B11, and 1C11 on the SARS-CoV, SARS-CoV-2, or MERS-CoV RBD, underlying their antiviral potency. Finally, a bispecific nanobody 3B11–1C11-Fc that binds to the SARS-CoV, SARS-CoV-2, and MERS-CoV RBDs exhibited high stability and robust cross-neutralizing activity against all tested SARS-CoV, SARS-CoV-2, and MERS-CoV strains, protecting mice from infection with these three coronaviruses. Overall, the identified nanobodies, particularly the bispecific nanobody, exhibit strong neutralizing potency and protective efficacy against SARS-CoV, SARS-CoV-2, and MERS-CoV, showing the potential for further therapeutic development.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: